Markets

Insider Trading

Hedge Funds

Retirement

Opinion

15 Most Important Medical Discoveries in History

In this article, we take a look at the 15 most important medical discoveries in history. You can skip our detailed analysis of the global medicine industry and go directly to the 5 Most Important Medical Discoveries in History.

Medical discoveries have done wonders for civilizations and helped humans to thrive. Since the evolution of modern technology, it has become easier for physicians and medical scientists to research new medicines and vaccines. The demand for medical treatments and medicines continues to rise, considering the increase in different diseases such as HIV, cancer, diabetes, tuberculosis, Alzheimer, and chronic respiratory diseases. In that regard, medical discoveries are more than necessary for humanity and the success of these discoveries is a must. 

Global Pandemic Impact

There are many deadly diseases, but a global pandemic can devastate the healthcare sector and to say the least, entire economies. For instance, the COVID-19 pandemic killed millions of people around the world. The lockdowns kept the entire world on hold, affecting the global economy. We are still witnessing the aftershocks of the COVID-19 pandemic as the world gradually recovers. In addition, we have experienced how a pandemic can drive the demand for pharmaceutical firms and medical centers. On January 18, IQVIA Holdings Inc. (NYSE:IQV) shared a report on the global use of medicines in 2023. IQVIA Holdings Inc.’s (NYSE:IQV) report highlights that the COVID-19 pandemic continues to drive pharmaceutical markets, and the global pharmaceutical market is expected to expand by $500 billion from 2020 through 2027. The pharmaceutical industry is mainly influenced by the vaccines being manufactured for COVID-19 patients. The senior vice president and executive director of the IQVIA Institute for Human Data Science, Murray Aitken mentioned that in the coming years, the transition of COVID-19 will enter a new phase, and vaccines and therapeutics will be available but used occasionally. 

Global Medicine Market Outlook

As we mentioned earlier, medicine is a fast-growing field worldwide. Countries are working to upgrade their healthcare system and support the sector through huge budget allotments. Some of the most advanced countries in medicine include South Korea, Japan, Denmark, and the U.S.  

As per IQVIA Holdings Inc.’s (NYSE:IQV) report, the global demand for medicines will rise sharply in the next five years. The global medicine market is expected to reach $1.9 trillion by 2027. The spending on medicine will grow at a rate of 3-6%, powered by new drug launches and recently launched drugs. Over the past 10 years, the medicine usage in daily doses soared by 36%. However, the report suggests slow growth through 2027, with an estimated daily dose usage of around 3.4 trillion, up by nearly 8% from the 2022 level. The developed economies are continuing to research new products in medicines. The regions expected to have the highest growth and adoption of novel medicines through 2027 include Latin America, Eastern Europe, and parts of Asia. 

In addition, the specialty medicine market is estimated to account for 43% of global medicine market spending in 2027. The total spending in developed markets is expected to be around 56%. Cancer remains one of the deadliest diseases worldwide. According to the World Health Organization, cancer accounted for 10 million deaths in 2020. The report from IQVIA Holdings Inc. (NYSE:IQV) has reported global spending on cancer drugs to reach $370 billion by 2027. Whereas, rare diseases such as Alzheimer’s and neurological disorders will speed spending growth in neurology driven by new therapies. 

Recent Medical Developments

The advancement in gene-editing is making an impact in the medical world. In recent times, CRISPR has emerged as one of the prolific developments in medical science and through this technology, scientists can alter genetic codes in almost any organism. Moreover, it is a cheaper and more precise technique in gene-editing compared to previous gene-editing methods. However, CRISPR does have drawbacks; for instance, DNA editing cures one mutation at a time. This can cause ever-lasting genetic changes and endure perpetual safety risks. At this point, there is a San Francisco-based biotechnology company, Amber Bio, that is working on RNA using CRISPR technology. Amber Bio is taking the next step in biotech to explore RNA and use CRISPR to potentially rectify a wide range of genetic disorders with minimum safety risks. On August 3, Amber Bio announced that they secured $26 million in seed funding. Playground Global led the seed funding round for the biotech company along with other participants including Hummingbird Ventures, Eli Lilly, and Andreessen Horowitz, among other firms. The investment will help Amber Bio bring top-notch scientists to its development team and continue its research on its RNA editing platform. Amber Bio’s co-founder Jacob Borrajo is motivated to innovate new genetic medicines. Borrajo says, “We want to innovate new genetic medicines that can extend broadly across diverse patient populations without the need to custom tailor to each specific mutation. That’s what gets us at Amber really excited and that’s what we’re building today.”

Scribe Therapeutics is another emerging company that is making notable developments in CRISPR-based genetic medicine. On July 25, Forbes shared that Scribe Therapeutics has potentially secured deals worth $4 billion with big pharmaceutical companies including Sanofi (NASDAQ:SNY) and Biogen Inc. (NASDAQ:BIIB). In 2018, Benjamin Oakes co-founded Scribe Therapeutics along with Jennifer Doudna, Brett Staahl, and David Savage. Scribe is working on the development of specialized CRISPR proteins to fight against various diseases such as amyotrophic lateral sclerosis (ALS), cancer, and sickle cell anemia, among others. In such a short time, the pharmaceutical firm has attracted huge partners and investors. 

After Scribe Therapeutics’ initial collaboration with Sanofi (NASDAQ:SNY) in September 2022, Scribe recently signed its second deal with Sanofi. On July 17, Scribe Therapeutics announced its new deal with Sanofi (NASDAQ:SNY), giving an exclusive license to Sanofi (NASDAQ:SNY) for the use of its CRISPR X-Editing (XE) genome editing technologies. With this deal, Sanofi (NASDAQ:SNY) will be able to make developments in vivo therapies such as sickle cell and other genetic diseases. Scribe has secured the deal with an upfront payment of $40 million and will potentially receive over $1.2 billion based on sale milestones. 

Biogen Inc. (NASDAQ:BIIB) and Sage Therapeutics, Inc. (NASDAQ:SAGE) are other renowned pharmaceutical firms working on major diseases including postpartum depression (PPD) and major depressive disorder (MDD) among women. Pregnant women are likely to face mental disorders due to PPD during and after pregnancy. According to the Centers for Disease Control and Prevention, 1 in 8 women experience symptoms of PPD in the U.S. On August 4, Biogen Inc. (NASDAQ:BIIB) and Sage Therapeutics, Inc. (NASDAQ:SAGE) received approval and a complete response letter from the U.S. Food and Drug Administration (FDA) for their PPD pill, Zurzuvae. This development is good news for both companies, which can possibly be the solution for millions of people affected by postpartum depression. Following the approval of Zurzuvae, Biogen Inc.’s (NASDAQ:BIIB) CEO Christopher A. Viehbacher made some comments:

“The approval of ZURZUVAE to treat postpartum depression is a major milestone for the hundreds of thousands of women who experience this underdiagnosed and undertreated condition. We appreciate the support of patients, patient advocates and researchers who helped to reach this milestone. We believe that ZURZUVAE will be an important option to treat PPD and we will thoroughly review the feedback from the FDA on the use of zuranolone in MDD to determine next steps.”

After the FDA approval of Zurzuvae, Reuters reported that analysts expect the stocks of both Biogen Inc. (NASDAQ:BIIB) and Sage Therapeutics, Inc. (NASDAQ:SAGE) to fall. Analysts believe that due to a smaller patient population of postpartum depression, there can be a negative sentiment among investors.

However, Biogen Inc. (NASDAQ:BIIB) has posted strong results. On July 25, the company reported earnings for the fiscal second quarter of 2023. The pharmaceutical firm posted revenue of $2.46 billion, beating estimates by $93.2 million. Biogen Inc. (NASDAQ:BIIB) reported earnings per share of $4.02, surpassing consensus by $0.26. During the Q2 2023 earnings call, Biogen Inc. (NASDAQ:BIIB) talked about the approval of Alzheimer’s treatment. The company believes its 100 mg/mL injection, LEQSEBI, is going to have a big impact on the practice of medicine. Here are some of the comments from the earnings call. 

“I’d like to start off with LEQSEBI. And I think before we really get into all the interesting details of commercialization and competitiveness, I just like to pause for a moment. This is an historic moment in healthcare history. We’re talking about the very first disease-modifying treatment that’s been approved fully — has received full approval from the FDA and reimbursement from CMS. And there have been literally dozens of medicines that have failed before this drug ever got to market. And that’s important for a couple of reasons, the first is that there is an awful lot we still don’t know. We are really at the beginning of a journey to really understand Alzheimer’s disease and how we can affect this disease.

But it’s also going to have a big impact on the practice of medicine. Physicians haven’t been able to really help patients very much beyond perhaps prescribing Donepezil or products like that. And the treatment that we are proposing here really is going to change an awful lot of how physicians practice and treat these patients. So as we start thinking about intent to prescribe and how physicians are looking at things, we’re actually not going to know that until we actually get out there on the marketplace and see how patients respond. ADUHELM did get approved. But as you all know, it never really got out of the blocks, and never really got launched. So this is really a first. And whenever you’re first, you’re going to discover an awful lot and a lot of this is just not that predictable.

So, I think the launch of the LEQSEBI is off to a very good start and we’ll, of course, keep you up to date as we get further patients. Now, move on to another slide here. One of the things that we’ve been doing an awful lot in the past months is really making sure that we are well-positioned for growth. And as we looked at the company, there’s where we were. As you know, today, we have a relatively mature product profile. Generally, when you have a mature product profile, you would expect the level of investment to go down. But we have actually relatively high operating expenses when we benchmark versus other companies. Part of that is an over-investment in legacy products. But we also have an extremely centralized governance. We’ve got many organizational levels.”

Biogen Inc. (NASDAQ:BIIB), Sage Therapeutics, Inc. (NASDAQ:SAGE), and Sanofi (NASDAQ:SNY) are among the top medical stocks in the industry, according to hedge funds. 

Our Methodology

To find data for the most important medical discoveries in history, we tracked the Nobel Prize winners in medicine. For the most important medical discoveries in history, we adopted a consensus approach. We choose the list of the most impactful Nobel Prize winners in medicine from Medscape, Regis College, and Nobel Prizes That Changed Medicine published by Imperial College Press. We then took the list of the 15 most important medical discoveries in history from each source, the top five, mid-five, and last five from the aforementioned sources, respectively. We took the list in the following pattern to give equal weight to top Nobel Prize winners in medicine, so we can have the most important medical discoveries across different time periods. The latest Nobel Prize winner in medicine is ranked higher. Here is the list of the 15 most important medical discoveries in history.

15 Most Important Medical Discoveries in History

15. Work on Serum Therapy

Year of Medical Discovery: 1901

Nobel Prize Winner: Emil von Behring 

In 1901, Emil von Behring got the prestigious Nobel Prize in Physiology or Medicine for his work on diphtheria antitoxin and serum therapy. Behring was the first Nobel Prize winner in medicine and is also known as the father of serum therapy. In 1891, a child suffering from diphtheria received the first successful therapeutic serum treatment. Emil von Behring’s work on serum therapy ranks 15th on our list of the most important medical discoveries in history. 

Some of the leading pharmaceutical companies in the world include Biogen Inc. (NASDAQ:BIIB), Sage Therapeutics, Inc. (NASDAQ:SAGE), and Sanofi (NASDAQ:SNY).

14. Work on the Physiology of Digestion

Year of Medical Discovery: 1904

Nobel Prize Winner: Ivan Pavlov  

Ivan Pavlov made a breakthrough in the physiology of digestion which allowed him to find conditioned reflexes. In 1904, Pavlov was awarded the Nobel Prize after he successfully defended his work on the physiology of digestion. Ivan Pavlov’s discovery is ranked among the most important medical discoveries in history.

13. Work on the Structure of the Nervous System

Year of Medical Discovery: 1906

Nobel Prize Winner: Camillo Golgi and Santiago Ramón y Cajal 

Camillo Golgi and Santiago Ramón y Cajal leaped forward in the discovery of the microscopic structure of the nervous system. In 1906, Golgi and Cajal were awarded the Nobel Prize for their work on the structure of the nervous system, which later helped in many complex physiological studies through technological advancement. Camillo Golgi and Santiago Ramón y Cajal’s work is ranked 13th on our list of the most important medical discoveries in history.

12. Work on the Physiology, Pathology, and Surgery of the Thyroid Gland

Year of Medical Discovery: 1909

Nobel Prize Winner: Emil Theodor Kocher 

Emil Theodor Kocher’s work on the physiology, pathology, and surgery of the thyroid gland made a major development in medical science. In 1909, Kocher got the Nobel Prize for his pioneering work on the thyroid gland. By 1917, more than 7,000 thyroid operations took place and nearly three-quarters were done by Kocher. Kocher’s work helped the mortality decrease from 14% in 1884 and 0.18% in 1898. Emil Theodor Kocher’s work is a major development in medical science and is ranked on our list of the most important medical discoveries in history.

11. Discovery of the Mechanism of the Electrocardiogram

Year of Medical Discovery: 1924

Nobel Prize Winner: Willem Einthoven 

Willem Einthoven’s discovery of the mechanism of the electrocardiogram, also known as ECG, was a breakthrough in medical history. Einthoven’s work in the field of heart physiology is ranked among the most important medical discoveries in history.

10. Discovery of Penicillin 

Year of Medical Discovery: 1945

Nobel Prize Winner: Sir Alexander Fleming, Ernst Boris Chain, and Sir Howard Walter Florey 

The discovery of penicillin is considered an evolution in medical science. In 1945, Sir Alexander Fleming, Ernst Boris Chain, and Sir Howard Walter Florey won the Nobel Prize in medicine for discovering penicillin and its therapeutic effect on various infectious diseases. The discovery of penicillin is ranked 10th on our list of the most important medical discoveries in history.

9. Deciphering the Genetic Code

Year of Medical Discovery: 1968

Nobel Prize Winner: Marshall Warren Nirenberg, Har Gobind Khorana, and Robert Holley

In 1968, Marshall Warren Nirenberg, Har Gobind Khorana, and Robert Holley’s work on deciphering the genetic code won the Nobel Prize in medicine. The discovery was based on a ribonucleic acid (RNA) consisting of a single nucleotide which led to a single amino acid. Through this, the scientists solved the first ever genetic code puzzle. Deciphering the genetic code makes our list of the most important medical discoveries in history.

8. Development of Radioimmunoassay 

Year of Medical Discovery: 1977

Nobel Prize Winner: Rosalyn Yalow

Rosalyn Yalow became the second woman to win the Nobel Prize in medicine in 1977. Yalow is known for her development of radioimmunoassay (RIA). This discovery introduced a groundbreaking method for the treatment of peptide hormones. Rosalyn Yalow’s development of radioimmunoassay is ranked eighth on our list of the most important medical discoveries in history.

7. Development of Computer Assisted Tomography

Year of Medical Discovery: 1979

Nobel Prize Winner: Allan MacLeod Cormack and Godfrey Hounsfield

Godfrey Hounsfield and Allan MacLeod Cormack contributed to the development of computer assisted tomography (CAT). For their discovery and work on the diagnosis of neurological disorders, Godfrey Hounsfield and Allan MacLeod Cormack were awarded the Nobel Prize in medicine in 1979. Hounsfield and Cormack’s invention is ranked seventh on our list of the most important medical discoveries in history.

6. Work on the Biochemistry and Physiology of Prostaglandins

Year of Medical Discovery: 1982

Nobel Prize Winner: John Robert Vane, Bengt Ingemar Samuelsson, and Sune Bergström 

In 1982, John Robert Vane, Bengt Ingemar Samuelsson, and Sune Bergström were awarded the Nobel Prize in medicine for their work on the biochemistry and physiology of prostaglandins. The use of prostaglandins in clinical medicine, particularly in obstetrics and gynecology has been really helpful. The work on the biochemistry and physiology of prostaglandins is ranked among the most important medical discoveries in history.

Pharmaceutical companies that are making major developments in medical science include Biogen Inc. (NASDAQ:BIIB), Sage Therapeutics, Inc. (NASDAQ:SAGE), and Sanofi (NASDAQ:SNY).

Click to continue reading and see the 5 Most Important Medical Discoveries in History.

Suggested Articles:

Disclosure: none. 15 Most Important Medical Discoveries in History is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…